{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Imovax",
    "query": {
      "intervention": "Imovax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Imovax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T03:17:41.608Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04019444",
      "title": "Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rabies",
        "Rabies Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd155-RG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rabies Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-09-19",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019444"
    },
    {
      "nct_id": "NCT02912845",
      "title": "Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "KamRAB - HRIG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kamada, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-08-01",
      "completion_date": "2019-11-13",
      "has_results": false,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912845"
    },
    {
      "nct_id": "NCT01784874",
      "title": "Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "Purified Vero Rabies Vaccine (VRVg) - Serum Free",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imovax® Rabies: inactivated rabies vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 408,
      "start_date": "2013-02",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2018-02-09",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 6,
      "location_summary": "Redding, California • Sacramento, California • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01784874"
    },
    {
      "nct_id": "NCT04062669",
      "title": "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        },
        {
          "name": "RabAvert",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2019-08-13",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 4,
      "location_summary": "South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04062669"
    },
    {
      "nct_id": "NCT04213950",
      "title": "Improving Adherence to Rabies PEP Guideline Recommendations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rabies",
        "Rabies Human",
        "Rabies Virus Infection"
      ],
      "interventions": [
        {
          "name": "Rabies PEP quality improvement bundle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 70,
      "start_date": "2019-12-29",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 15,
      "location_summary": "Baytown, Texas • Cypress, Texas • Houston, Texas + 7 more",
      "locations": [
        {
          "city": "Baytown",
          "state": "Texas"
        },
        {
          "city": "Cypress",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213950"
    },
    {
      "nct_id": "NCT00000884",
      "title": "A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC-HIV MN120TMG (vCP205)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC-RG Rabies Glycoprotein (vCP65)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": null,
      "completion_date": "2000-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000884"
    },
    {
      "nct_id": "NCT00031070",
      "title": "Increasing HAART-Induced Immune Restoration With Cyclosporine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Abacavir sulfate, Lamivudine and Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis A Vaccine (Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine, Heptavalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rabies Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031070"
    },
    {
      "nct_id": "NCT03961555",
      "title": "Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "SYN023",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HRIG (HyperRab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rabies vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Synermore Biologics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2019-09-03",
      "completion_date": "2021-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Milan",
          "state": "Tennessee"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03961555"
    },
    {
      "nct_id": "NCT02956746",
      "title": "A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Human Rabies"
      ],
      "interventions": [
        {
          "name": "SYN023",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imovax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RabAvert",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HyperRAB ST (human rabies immune globulin)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Synermore Biologics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 164,
      "start_date": "2016-08",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02956746"
    },
    {
      "nct_id": "NCT02374814",
      "title": "Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "Rabies vaccine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York - Upstate Medical University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2015-03-24",
      "completion_date": "2016-09-22",
      "has_results": true,
      "last_update_posted_date": "2022-06-13",
      "last_synced_at": "2026-09-05T03:17:41.608Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374814"
    }
  ]
}